The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 3 of 13
Back to Result List

Immune thrombocytopenia in two unrelated Fanconi anemia patients - a mere coincidence?

Please always quote using this URN: urn:nbn:de:bvb:20-opus-149837
  • Thrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA), are interpreted either as progression to bone marrow failure or as developing myelodysplasia. On the other hand, immune thrombocytopenia (ITP) represents an acquired and often self-limiting benign hematologic disorder, associated with peripheral, immune-mediated, platelet destruction requiring different management modalities than those used in congenital bone marrow failure syndromes, including FA. Here, we describe the clinical course of two independent FAThrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA), are interpreted either as progression to bone marrow failure or as developing myelodysplasia. On the other hand, immune thrombocytopenia (ITP) represents an acquired and often self-limiting benign hematologic disorder, associated with peripheral, immune-mediated, platelet destruction requiring different management modalities than those used in congenital bone marrow failure syndromes, including FA. Here, we describe the clinical course of two independent FA patients with atypical – namely immune – thrombocytopenia. While in one patient belonging to complementation group FA-A, the ITP started at 17 months of age and showed a chronically persisting course with severe purpura, responding well to intravenous immunoglobulins (IVIG) and later also danazol, a synthetic androgen, the other patient (of complementation group FA-D2) had a self-limiting course that resolved after one administration of IVIG. No cytogenetic aberrations or bone marrow abnormalities other than FA-typical mild dysplasia were detected. Our data show that acute and chronic ITP may occur in FA patients and impose individual diagnostic and therapeutic challenges in this rare congenital bone marrow failure/tumor predisposition syndrome. The management and a potential context of immune pathogenesis with the underlying marrow disorder are discussed.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Anna Karastaneva, Sofia Lanz, Angela Wawer, Uta Behrends, Detlev Schindler, Ralf Dietrich, Stefan Burdach, Christian Urban, Martin Benesch, Markus G. Seidel
URN:urn:nbn:de:bvb:20-opus-149837
Document Type:Journal article
Faculties:Medizinische Fakultät / Institut für Humangenetik
Language:English
Parent Title (English):Frontiers in Pediatrics
Year of Completion:2015
Volume:3
Issue:50
Source:Frontiers in Pediatrics 2015, 3, 50. DOI: 10.3389/fped.2015.00050
DOI:https://doi.org/10.3389/fped.2015.00050
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/PMC4459098
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:DNA repair defect; Evans syndrome; FANCA; FANCD2; Fanconi anemia; bone marrow failure syndrome; danazol; immune thrombocytopenia
Release Date:2019/01/22
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International